Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Is that clear?

    How Vermont's drug price transparency law could pave the way for price controls

    Vermont's drug price transparency law is part of a national strategy that is aiming for price controls.

    Published on 6/27/2016
  • Box: PhRMA explains

    Is that clear? PhRMA explains In March 30 testimony about Vermont's drug price transparency law, PhRMA Assistant General Counsel John Murphy discussed the industry's perspective on drug pricing. The PhRMA …

    Published on 6/27/2016
  • Figure: Transparency provisions

    Is that clear? Transparency provisions Vermont is the first state to enact a drug price transparency law, but at least a dozen were introduced in state legislatures during 2015-16. Some of them have expired …

    Published on 6/27/2016
  • Fireside with Califf

    FDA Commissioner Califf's priorities on patients, communication and FDA staffing

    FDA's Robert Califf says industry should communicate directly with patients, and more progress is needed to match patients with experimental drugs.

    Published on 6/20/2016
  • Califf gets precise

    How Califf sees FDA's role in the Precision Medicine Initiative

    Robert Califf on why he turned from skeptic to advocate for exploiting genomics in precision medicine.

    Published on 6/20/2016
  • Triple's shot

    ASCO 2016: How triple-negative breast cancer landscape is evolving

    A handful of abstracts at ASCO suggest that targeted therapies could finally be on the horizon for triple-negative breast cancer.

    Published on 6/13/2016
  • Box: PARP pick-me-up

    Triple's shot PARP pick-me-up Triple-negative breast cancer certainly isn't underserved due to lack of trying. Many targeted agents have made it to Phase II testing only to fail. In 2013, Roche and its Genentech …

    Published on 6/13/2016
  • Figure: Breast cancer breakdown

    Triple's shot Breast cancer breakdown Triple-negative makes up about 20% of all breast cancer cases, similar to HER2+. The remainder are hormone receptor-positive for estrogen receptor (ER) and/or progesterone …

    Published on 6/13/2016
  • Rushing to America

    Behind China's rush to access U.S. biotechs

    Chinese investors are rushing into U.S. biotechs to access innovations, add assets or take advantage of arbitrage.

    Published on 6/6/2016
  • Figure: China's cross-border cash

    Rushing to America China’s cross-border cash Selected Chinese firms that manage more than $5.5 billion in aggregate are seeking U.S. healthcare companies to add to their portfolios. Not shown is YuanMing Capital, …

    Published on 6/6/2016
  • Figure: Meet the Founders

    Rushing to America Meet the Founders

    Published on 6/6/2016
  • Figure: U.S. deals by Chinese investors

    Rushing to America U.S. deals by Chinese investors Five Chinese firms that are seeking access to innovation in the U.S. have disclosed investments in a total of 33 U.S. biotechs. The number of U.S. companies each …

    Published on 6/6/2016
  • Taking Takeda global

    How Takeda CEO Weber plans to claim top-tier positions in GI, cancer, CNS

    How Takeda's Christophe Weber expects to claim a top-tier position in at least two of the company's three therapeutic areas within 5-10 years.

    Published on 5/30/2016
  • Figure: Global focus

    Taking Takeda global Global focus Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) has disclosed 23 clinical programs. Cancer accounts for the most products, with 10 programs covering all phases of clinical development…

    Published on 5/30/2016
  • Figure: Leadership development

    Taking Takeda global Leadership development As part of a globalization strategy, Takeda Pharmaceutical Co. Ltd. President and CEO Christophe Weber assembled a new 14-member executive team and filled six of the …

    Published on 5/30/2016
  • Figure: Tracking Takeda

    Taking Takeda global Tracking Takeda Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) wants to maintain its position in the top 10 cancer companies and become the number one GI company in the next five to 10 years. …

    Published on 5/30/2016
  • Figure: Courting cancer

    Two heads are better Courting cancer The early stage deals completed by Novartis AG (NYSE:NVS; SIX:NOVN) since 2013 show the pharma has largely focused its pipeline building efforts in the two therapeutic areas of…

    Published on 5/23/2016
  • Figure: Novartis Executive Committee

    Two heads are better Novartis Executive Committee

    Published on 5/23/2016
  • Figure: Splitting for focus

    Two heads are better Splitting for focus Novartis AG (NYSE:NVS; SIX:NOVN) will split its innovative drug development division into two business units: Novartis Oncology and Novartis Pharmaceuticals. The oncology …

    Published on 5/23/2016
  • Two heads are better

    What Novartis needs to do beyond reorganization to grow innovation

    Novartis' new oncology unit appears to be set up for growth, but the pharmaceuticals unit may need more deals to stock its pipeline.

    Published on 5/23/2016
  • Figure: Capital rationing

    Global ambitions Capital rationing Last year, the average raised per private European company increased by 47% to $22.2 million from $15.1 million in 2014, helped by a few companies that secured significant funds.…

    Published on 5/16/2016
  • Figure: Clinical rationing

    Global ambitions Clinical rationing The total raised by private and public European biotechs with lead programs in clinical development rose by 42% to $4.7 billion in 2015 from $3.3 billion in 2014. The increase …

    Published on 5/16/2016
  • Figure: Competition for capital

    Global ambitions Competition for capital Total funding continued to increase in the U.S. and the EU, but European-domiciled companies continued to receive a modest share of the total. Last year, the money raised …

    Published on 5/16/2016
  • Figure: Hallmarks of ambition

    Global ambitions Hallmarks of ambition The 15 U.S. VCs who invested in the greatest number of rounds worldwide during 2010-15 put their money to work in Europe in innovative companies with ambitious pipelines, …

    Published on 5/16/2016
  • Figure: Missed opportunity

    Global ambitions Missed opportunity Between the start of 2013 and mid-2015, U.S. biotech share prices grew at nearly twice the rate of their European counterparts. But even as U.S. investors began to complain that…

    Published on 5/16/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993